APO.RT Acasti Pharma

Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM

Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM
EN
01/10/2020

Underlying

APO.RTAcasti Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acasti Pharma

Free Trial
APO.RT ACASTI PHARMA

Acasti Pharma Inc: 1 director

A director at Acasti Pharma Inc bought 676,371 shares at 1.848USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

09/28/23 September 28, 2023 1 EN
 PRESS RELEASE
Free
APO.RT ACASTI PHARMA

Acasti Pharma Reports Third Quarter 2023 Operational Results

Acasti Pharma Reports Third Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the third quarter ended December 31, 2022 Recent Highlights The Company anticipates receiving clarifying guidance from the Food and Drug Administration (FDA) on its proposed p...

February 14, 2023 1 EN
 PRESS RELEASE
Free
APO.RT ACASTI PHARMA

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid...

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that it has received notification from the NASDAQ Listing Qualifications Department ("NASDAQ") that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement for contin...

January 25, 2023 1 EN
 PRESS RELEASE
Free
APO.RT ACASTI PHARMA

Acasti Pharma to Present at Lytham Partners Investor Select Conference...

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D’Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023. Company Webcast The Company's webcast presentation will be available f...

January 24, 2023 1 EN
 PRESS RELEASE
Free
APO.RT ACASTI PHARMA

Acasti Pharma to Present at Sidoti Virtual Investor Conference on Janu...

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023. The presentation will begin at 3:15pm ET on Wednesday, January 18, 2023 and can be a...

January 13, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch